Phase I trial of ESN 364 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2015
Price : $35 *
At a glance
- Drugs Fezolinetant (Primary)
- Indications Endometriosis; Polycystic ovary syndrome; Uterine leiomyoma
- Focus Adverse reactions; First in man
- 14 Dec 2015 Results published in the Journal of Clinical Endocrinology and Metabolism
- 08 Dec 2014 Results published in a Euroscreen media release.
- 18 Dec 2013 Status changed from planning to recruiting, as reported by a Euroscreen media release.